Test Code TOPU Targeted Opioid Mass Spectrometry Screen, Random, Urine (Non-Orderable)
Specimen Required
Only orderable as part of profile. For more information see:
CSMHP / Controlled Substance Monitoring Hybrid Plus Drug Profile, 19 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
PMHPU / Pain Management Hybrid Profile, 22 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube: Plastic urine container
Submission Container/Tube: Plastic, 5-mL tube
Specimen Volume: 1 mL
Collection Instructions:
1. Collect a random urine specimen.
2. No preservative
Useful For
Only orderable as part of profile. For more information see:
CSMHP / Controlled Substance Monitoring Hybrid Plus Drug Profile, 19 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
PMHPU / Pain Management Hybrid Profile, 22 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
Qualitatively (present vs not detected) identifying 31 opioid compounds (parent drug and metabolites) in urine to help determine compliance or identify illicit opioid drug use
This test is not intended for use in employment-related testing.
Method Name
Only orderable as part of profile. For more information see:
CSMHP / Controlled Substance Monitoring Hybrid Plus Drug Profile, 19 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
PMHPU / Pain Management Hybrid Profile, 22 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
Liquid Chromatography Tandem Mass Spectrometry, High-Resolution Accurate Mass (LC-MS/MS HRAM)
Reporting Name
Targeted Opioid MS Screen, USpecimen Type
UrineSpecimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Urine | Refrigerated (preferred) | 14 days |
| Frozen | 28 days | |
| Ambient | 72 hours |
Reject Due To
| Gross hemolysis | Reject |
| Gross icterus | Reject |
Reference Values
Only orderable as part of profile. For more information see:
CSMHP / Controlled Substance Monitoring Hybrid Plus Drug Profile, 19 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
PMHPU / Pain Management Hybrid Profile, 22 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
Not detected (Positive results are reported with qualitative "Present" results)
Cutoff concentrations:
Codeine: 25 ng/mL
Codeine-6-beta-glucuronide: 100 ng/mL
Morphine: 25 ng/mL
Morphine-6-beta-glucuronide: 100 ng/mL
6-Monoacetylmorphine: 25 ng/mL
Hydrocodone: 25 ng/mL
Norhydrocodone: 25 ng/mL
Dihydrocodeine: 25 ng/mL
Hydromorphone: 25 ng/mL
Hydromorphone-3-beta-glucuronide: 100 ng/mL
Oxycodone: 25 ng/mL
Noroxycodone: 25 ng/mL
Oxymorphone: 25 ng/mL
Oxymorphone-3-beta-glucuronide: 100 ng/mL
Noroxymorphone: 25 ng/mL
Fentanyl: 2 ng/mL
Norfentanyl: 2 ng/mL
Meperidine: 25 ng/mL
Normeperidine: 25 ng/mL
Naloxone: 25 ng/mL
Naloxone-3-beta-glucuronide: 100 ng/mL
Methadone: 25 ng/mL
2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine: 25 ng/mL
Tramadol: 25 ng/mL
O-desmethyltramadol: 25 ng/mL
Tapentadol: 25 ng/mL
N-desmethyltapentadol: 50 ng/mL
Tapentadol-beta-glucuronide: 100 ng/mL
Buprenorphine: 5 ng/mL
Norbuprenorphine: 5 ng/mL
Norbuprenorphine glucuronide: 20 ng/mL
Interpretation
If an opioid or its corresponding metabolites are identified (present), it indicates that the patient has used the respective opioid in the recent past. The absence of expected opioids or their metabolites may indicate noncompliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted or adulterated urine, or limitations of testing. The concentration of the drug must be greater than or equal to the cutoff to be reported as present. If a specific drug concentration is required, the laboratory must be contacted within 2 weeks of specimen collection/testing to request quantification by a second analytical technique at an additional charge.
Day(s) Performed
Monday through Sunday
Report Available
2 to 4 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
CPT Code Information
G0481
80364 (if appropriate for select payers)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| TOPU | Targeted Opioid MS Screen, U | 95796-9 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 624213 | Codeine | 19411-8 |
| 624214 | Codeine-6-beta-glucuronide | 89310-7 |
| 624215 | Morphine | 19597-4 |
| 624216 | Morphine-6-beta-glucuronide | 89308-1 |
| 624217 | 6-monoacetylmorphine | 19321-9 |
| 624218 | Hydrocodone | 19482-9 |
| 624219 | Norhydrocodone | 89304-0 |
| 624220 | Dihydrocodeine | 19446-4 |
| 624221 | Hydromorphone | 19486-0 |
| 624222 | Hydromorphone-3-beta-glucuronide | 89309-9 |
| 624223 | Oxycodone | 19642-8 |
| 624224 | Noroxycodone | 89303-2 |
| 624225 | Oxymorphone | 19646-9 |
| 624226 | Oxymorphone-3-beta-glucuronide | 89301-6 |
| 624227 | Noroxymorphone | 89302-4 |
| 624228 | Fentanyl | 59673-4 |
| 624229 | Norfentanyl | 43199-9 |
| 624230 | Meperidine | 19532-1 |
| 624231 | Normeperidine | 27920-8 |
| 624232 | Naloxone | 42618-9 |
| 624233 | Naloxone-3-beta-glucuronide | 89307-3 |
| 624234 | Methadone | 19550-3 |
| 624235 | EDDP | 93495-0 |
| 624236 | Tramadol | 19710-3 |
| 624237 | O-desmethyltramadol | 86453-8 |
| 624238 | Tapentadol | 72485-6 |
| 624239 | N-desmethyltapentadol | 89306-5 |
| 624240 | Tapentadol-beta-glucuronide | 89300-8 |
| 624241 | Buprenorphine | 93494-3 |
| 624242 | Norbuprenorphine | 82371-6 |
| 624243 | Norbuprenorphine glucuronide | 89305-7 |
| 624244 | Opioid Interpretation | 69050-3 |